… increased sensitivity to paclitaxel-cisplatin-based neoadjuvant … of cyclophosphamide, epirubicin, paclitaxel, and docetaxel. During … consisting of docetaxel, paclitaxel, epirubicin, and cyclophosphamide … of patients with prostate cancer. Front Oncol. …

… delivering stronger epigenetic effects than Paclitaxel or Rapamycin in aggressive PC3 … in aggressive human prostate cancer cells-achieving greater efficacy than Paclitaxel and Rapamycin …

… 107 cervical cancer,108 prostate cancer,109 and colon … curcumin, doxorubicin, naringenin, paclitaxel, and quercetin. They were … ZnO nanocarrier loaded with paclitaxel as drug delivery … graphene oxide nanocomposite for paclitaxel delivery and enhanced toxicity …

… by approximately 50% in a prostate cancer animal model with aggressive cancer … and mortality when combined with Paclitaxel—a widely used chemotherapy but … For Antibacterial Treatment, Tissue Regeneration Paclitaxel and other chemotherapy agents induce …

… prostate tumors in the bone microenvironment. Mesenchymal stem cells induce already disseminated prostate cancer … facilitating metastatic prostate tumor growth in … stem cells into prostate tumours promotes metastasis. … inhibitor, and paclitaxel in patients …

… de novo metastatic hormone-sensitive prostate cancer. Data for overall survival ( … trial, which combined Truqap with paclitaxel, found no significant OS benefit … patients with metastatic castration-resistant prostate cancer (mCRPC) versus Xtandi alone. These …

… apoptosis and autophagy in prostate cancer cells,22 while … thereby enhancing sensitivity to paclitaxel. Preclinical studies indicate … pro-death events in prostate cancer. Biomolecules. 2020;10 … progression and determines paclitaxel chemosensitivity through B- …

… making inroads in a prostate cancer subtype. High-level … -sensitive prostate cancer (mHSPC), a specific type of prostate cancer with … with metastatic castration-resistant prostate cancer (mCRPC) with PTEN … of Truqap and chemotherapy paclitaxel were roughly the …

… Z, et al. Celecoxib augments paclitaxel-induced immunogenic cell death in … and photothermal therapy of targeted prostate cancer. J Mater Chem B. 2022 … , Reis CP. Advances in localized prostate cancer: a special focus on photothermal …

… refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). Based … preclinical activity in prostate cancer models against both … in combination with paclitaxel for the treatment … with metastatic castration-resistant prostate cancer (NCT05156905), and …